Turning Point Brands Dips on FDA Concerns
Business & Finance News Today | 2 Min News | The Daily News Now! · The Daily News Now!
Audio is streamed directly from the publisher (api.fastcast.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Turning Point Brands stock plummeted 15.5% due to FDA concerns over nicotine pouch approvals. These tobacco-free, easy-to-use products have been driving growth, with the segment surging 266% in Q1. Despite a 50% drop in shares, the companys pouch revenue is projected to reach $180-$190 million by 2026. The FDAs pause on licenses due to health risks and teen appeal may be a short-term issue, presenting a value opportunity for investors in tobacco alternatives.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
[email protected]
This is an automated, high-level news summary based on public reporting.
Report issues to [email protected].
View sources & latest updates:
https://sources.thednn.ai/9f1781970c2a76a6